Fascioliasis Market, By Drug (Triclabendazole, Albendazole, and Nitazoxanide), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), And by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Afr

Fascioliasis is an infectious disease usually caused by Fasciola hepatica, also called as the common liver fluke or the sheep liver fluke. Fascioliasis is caused by two fasciola species, the main species Fasciola hepatica, and another related species Fasciola gigantica, which also can infect people. Fasciola gigantica has been found in some tropical areas such as Australia, China. Fascioliasis is found where sheep or cattle are reared. People are infected with Fasciola when the parasite is accidentally ingested (swallowed) through raw watercress or other contaminated freshwater plants, and also by drinking contaminated water. Other ways include by eating vegetables that were washed or irrigated with contaminated water. Fasciola infection can be prevented by not eating raw watercress and other water plants, especially from endemic grazing areas. Some people feel sick during the early stage of infection, while immature flukes migrate from the intestine through the abdominal cavity and liver. Fasciola infection is both treatable and preventable.

Market Dynamics

Increasing adoption of inorganic strategies such as product approvals by the U.S. Food and Drug Administration is expected to drive the global fascioliasis market growth over the forecast period. For instance, in February 2019, Novartis AG, a pharmaceutical company, announced that they had received an approval from the U.S.Food and Drug Administration for triclabendazole (Egaten) for the treatment of fascioliasis in patients aged 6 years and older. The approval of triclabendazole in the U.S. is expected to facilitate drug licensing and import to endemic countries, to provide a help for the sufficient availability of the drug when needed.

Key features of the study:

• This report provides an in-depth analysis of the global fascioliasis market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global fascioliasis market based on the following parameters–company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Novartis AG, AMGIS Lifescience Ltd., Romark, AbbVie Inc., Merck KGaA, AdvaCare Pharma, Intas Pharmaceuticals Ltd., Procyon Life Sciences, Adroit Pharmachem Pvt Ltd., Sun Pharmaceutical Industries Ltd., RV Lifesciences Limited, Grampus Laboratories, and Janssen Pharmaceuticals, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global fascioliasis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fascioliasis market

• Global Fascioliasis Market, By Drug:
• Triclabendazole
• Albendazole
• Nitazoxanide
• Global Fascioliasis Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Fascioliasis Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Country/Region
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Novartis AG
• AMGIS Lifescience Ltd.
• Romark
• AbbVie Inc.
• Merck KGaA
• AdvaCare Pharma
• Intas Pharmaceuticals Ltd.
• Procyon Life Sciences
• Adroit Pharmachem Pvt Ltd.
• Sun Pharmaceutical Industries Ltd.
• RV Lifesciences Limited
• Grampus Laboratories
• Janssen Pharmaceuticals, Inc.